The UK’s National Health Service NHS is eyeing psychedelic drugs like psilocybin, found in magic mushrooms, as potential treatments for depression. Since 2022, multiple clinical trials have explored their use, with early findings suggesting they could offer rapid, lasting relief for patients unresponsive to traditional antidepressants. Researchers at Imperial College London and other institutions have led these studies, with some participants reporting improvements after just two or three sessions combined with therapy. The drugs work by disrupting rigid thought patterns linked to depression, unlike daily medication that may take weeks to show effects. While findings remain preliminary, the results have sparked serious discussion among policymakers and mental health experts about integrating psychedelics into NHS care. The UK’s Medicines and Healthcare products Regulatory Agency has not yet approved any psychedelic treatments, but advocates argue the evidence is strong enough to warrant further trials and policy changes.

Growing interest in psychedelics for mental health

The push for psychedelic therapies comes as depression cases rise in the UK, with NHS England reporting a 24% increase in referrals for talking therapies in 2023 alone. Traditional antidepressants, while effective for some, fail to help nearly a third of patients. Psychedelics like psilocybin and MDMA, currently classified as Schedule 1 drugs, are being re-evaluated for their therapeutic potential. In 2023, Australia became the first country to legalize MDMA and psilocybin for prescription use in severe depression and PTSD, setting a precedent for other nations. UK researchers are closely monitoring these developments, with some calling for expedited trials to assess safety and efficacy. Critics, however, warn that long-term risks remain unclear and that legalization could lead to misuse without strict controls.

NHS faces logistical and ethical challenges

Integrating psychedelic treatments into the NHS poses significant challenges. Unlike standard medications, these therapies require specialized settings, trained therapists, and careful patient screening to prevent adverse reactions. The cost of training staff and setting up treatment rooms could strain already overburdened mental health services. Ethical concerns also arise, particularly around consent, as depression can impair judgment. Proponents argue that the potential benefits—such as reduced suicide rates and shorter recovery times—outweigh the risks, especially for patients with treatment-resistant depression. Meanwhile, the Royal College of Psychiatrists has called for cautious optimism, urging more peer-reviewed research before any policy shifts. A spokesperson for the NHS confirmed it is monitoring global progress but has no immediate plans to adopt psychedelic therapies.

Researchers emphasize that psychedelics are not a magic cure but a tool that must be used alongside therapy. Studies show the drugs’ effects are short-lived, with benefits tied to the therapeutic sessions that follow. This model differs from traditional pharmaceutical treatments, which rely on daily medication. The Johns Hopkins University Center for Psychedelic and Consciousness Research, a leader in the field, has published multiple studies highlighting psilocybin’s ability to reduce depression and anxiety in cancer patients. UK trials are now expanding to include broader patient groups, with results expected by 2025. If successful, these studies could accelerate regulatory approval and pave the way for NHS adoption. For now, the debate hinges on balancing innovation with safety, as the UK weighs the future of mental healthcare.

What happens next for NHS and psychedelic therapies

The next phase of research will focus on large-scale trials involving hundreds of patients across multiple UK sites. These studies aim to replicate earlier findings and address lingering questions about dosage, long-term effects, and patient selection. The NHS has signaled it will collaborate with universities and private sector partners to fund and conduct these trials. Meanwhile, campaign groups like Breaking Convention continue lobbying for faster action, citing urgent patient needs. Policymakers are expected to review data from Australia and the U.S., where states like Oregon have legalized psilocybin therapy. A decision on NHS integration could come within two years if trials yield consistent positive results. Until then, patients seeking psychedelic treatments must rely on private clinics or travel abroad, where some countries already allow legal use. The outcome of these trials may redefine mental health care in the UK and beyond.

What You Need to Know

  • Source: BBC News
  • Published: January 02, 2026 at 15:47 UTC
  • Category: Environment
  • Topics: #bbc · #environment · #climate · #health · #research · #medicine

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on BBC News →

All reporting rights belong to the respective author(s) at BBC News. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · January 02, 2026

🇧🇷 Resumo em Português

O Reino Unido pode estar prestes a revolucionar o tratamento da depressão com uma terapia inusitada: os “cogumelos mágicos”. Estudos clínicos recentes, realizados desde 2022, indicam que a psilocibina — substância ativa dos chamados cogumelos alucinógenos — pode oferecer resultados promissores no combate à doença, que afeta milhões de pessoas no mundo. Enquanto países como o Canadá já avançam na regulamentação do uso terapêutico, a discussão ganha força também no Brasil, onde a saúde mental enfrenta desafios crescentes e a busca por alternativas inovadoras se torna cada vez mais urgente.

No Brasil, onde a depressão atinge cerca de 12 milhões de pessoas, segundo a Organização Mundial da Saúde (OMS), a possibilidade de usar psilocibina em tratamentos representa não apenas uma esperança para pacientes resistentes a métodos tradicionais, mas também um debate ético e científico. Embora a substância ainda seja classificada como ilegal no país, pesquisadores brasileiros já manifestam interesse em estudos controlados, especialmente diante do potencial da terapia para reduzir sintomas em casos graves. O tema, no entanto, esbarra em barreiras regulatórias e preconceitos culturais, que precisam ser superados para que o Brasil não fique para trás em uma possível revolução no tratamento de doenças mentais.

Se a psilocibina for aprovada para uso médico no Reino Unido, o Brasil terá de acelerar discussões sobre o tema, sob risco de perder oportunidades terapêuticas que poderiam aliviar o sofrimento de milhões.